• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $RNAC

    Cartesian Therapeutics Inc.

    Subscribe to $RNAC
    $RNAC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2016

    Exchange: NASDAQ

    Recent Analyst Ratings for Cartesian Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    12/19/2024$42.00Buy
    BTIG Research
    8/6/2024Buy
    TD Cowen
    7/2/2024Outperform → Perform
    Oppenheimer
    6/4/2024$50.00Outperform
    Oppenheimer
    5/24/2024$40.00Buy
    Mizuho
    4/23/2024$2.00 → $54.00Buy
    H.C. Wainwright
    4/23/2024$39.00Outperform
    Leerink Partners
    See more ratings

    Cartesian Therapeutics Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

      FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors.

      5/30/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

      FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company's website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a

      5/13/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

      Initiation of Phase 3 AURORA trial of Descartes-08 in myasthenia gravis expected in 2Q25; deep and sustained benefits observed through Month 12 after a single course of therapy in Phase 2b trial Preliminary data from Phase 2 trial of Descartes-08 in systemic lupus erythematosus expected in 2H25 Initiation of Phase 2 pediatric basket trial of Descartes-08 in select autoimmune indications expected in 2H25 Approximately $182.1 million cash, cash equivalents and restricted cash as of March 31, 2025 expected to support planned operations into mid-2027, including completion of planned Phase 3 AURORA trial FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc.

      5/8/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces New Employment Inducement Grants

      FREDERICK, Md., May 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for the treatment of autoimmune diseases, today announced the granting of inducement awards to five new employees. On May 1, 2025, the Company issued to these employees options to purchase an aggregate of 27,700 shares of the Company's common stock with an exercise price of $12.27, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved

      5/2/25 7:05:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

      After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in Descartes-08-treated participants who did not have prior exposure to biologic therapies, with an average 7.1-point reduction in MG-ADL and 57% of patients in this subgroup maintaining minimum symptom expression at Month 12 Safety profile consistent with previously reported data and continues to support outpatient administration Phase 3 AURORA trial on track to dose first patient in 2Q25 FREDERICK, Md., April 08, 2025 (GLOBE NEWSWIRE) -

      4/8/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces New Employment Inducement Grants

      FREDERICK, Md., April 02, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On April 1, 2025, the Company issued to these employees options to purchase an aggregate of 31,000 shares of the Company's common stock with an exercise price of $12.49, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were ap

      4/2/25 7:05:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

      FREDERICK, Md., April 01, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 2:15 p.m. ET. A live webcast of the presentation and fireside chats is expected to be accessible in the Events section of the Company's website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a clinica

      4/1/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

      Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25; Deep and durable responses maintained over 12 months in Descartes-08-treated participants in Phase 2b trial Phase 2 trial of Descartes-08 in systemic lupus erythematosus ongoing with expected data readout in 2H25 Company expects to initiate Phase 2 pediatric basket trial of Decartes-08 in select autoimmune indications in 2H25 Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $214.3 million cash, cash equivalents and restricted cash as of December 31, 2024 expected to support planned operations into mid-2027, including completion of planned Phase 3 AURORA trial FREDERICK, M

      3/13/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces New Employment Inducement Grant

      FREDERICK, Md., March 06, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of an inducement award to one new employee. On March 3, 2025, the Company issued to this employee an option to purchase 2,650 shares of the Company's common stock with an exercise price of $17.50, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The option was granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the C

      3/6/25 7:05:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics to Participate in Upcoming Investor Conferences

      FREDERICK, Md., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapies for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in February and March: A fireside chat at the H.C. Wainright & Co. 3rd Annual Cell Therapy Virtual Conference at 1:00 p.m. ET on Tuesday, February 25, 2025A presentation at the TD Cowen 45th Annual Health Care Conference at 1:50 p.m. ET on Monday, March 3, 2025 in Boston, MAA fireside chat at the Leerink Global Healthcare Conference at 8:40 a.m. ET on Monday, March 10, 2025 in Miami, FL A li

      2/18/25 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Springer Timothy A bought $1,522,517 worth of shares (149,075 units at $10.21), increasing direct ownership by 0.26% to 8,643,685 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      4/11/25 5:29:40 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $1,371,154 worth of shares (89,863 units at $15.26), increasing direct ownership by 1% to 8,621,325 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      3/20/25 7:50:25 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $366,354 worth of shares (20,967 units at $17.47), increasing direct ownership by 0.25% to 8,531,462 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/15/25 4:08:27 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $965,021 worth of shares (52,189 units at $18.49), increasing direct ownership by 0.62% to 8,507,895 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      12/23/24 5:20:43 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $7,373,527 worth of shares (431,940 units at $17.07), increasing direct ownership by 5% to 8,455,706 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      11/18/24 7:35:50 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A acquired 2,119,193 shares, bought $4,293,545 worth of shares (205,721 units at $20.87) and disposed of 2,119,193 shares, increasing direct ownership by 33% to 8,023,766 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      10/4/24 5:58:13 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $101,968 worth of shares (8,016 units at $12.72) (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      8/14/24 4:43:58 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Barabe Timothy C bought $95,250 worth of shares (7,500 units at $12.70), increasing direct ownership by 53% to 21,766 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      8/14/24 4:41:54 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Springer Timothy A bought $11,442 worth of shares (18,400 units at $0.62) (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      3/28/24 5:11:38 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Springer Timothy A bought $11,398 worth of shares (19,044 units at $0.60) (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      3/20/24 5:09:02 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

      Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase

      11/7/24 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

      Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected to support development of Descartes-08 in MG through planned Phase 3 trial GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today rep

      8/8/24 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Strengthens Board of Directors with Appointment of Kemal Malik

      GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. "We are thrilled to welcome Dr. Malik, a proven leader and industry veteran, to our Board of Directors," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "His deep experience in successfully advancing innovative therapies through all st

      7/2/24 4:05:00 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. SEC Filings

    See more
    • Cartesian Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/30/25 7:02:49 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Cartesian Therapeutics Inc.

      S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/8/25 7:13:14 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Cartesian Therapeutics Inc.

      10-Q - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/8/25 7:05:43 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      5/8/25 7:04:07 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      4/29/25 8:01:37 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Cartesian Therapeutics Inc.

      DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      4/28/25 4:42:02 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Cartesian Therapeutics Inc.

      DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      4/28/25 4:41:15 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Cartesian Therapeutics Inc.

      SCHEDULE 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      4/25/25 2:57:46 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      4/8/25 7:04:45 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Cartesian Therapeutics Inc.

      10-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      3/13/25 7:06:47 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 16% to 55,226 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      5/14/25 4:15:52 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operations Officer English Emily exercised 7,500 units of Common Stock at a strike of $3.30, increasing direct ownership by 19% to 47,726 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      4/16/25 4:35:51 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $1,522,517 worth of shares (149,075 units at $10.21), increasing direct ownership by 0.26% to 8,643,685 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      4/11/25 5:29:40 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $1,371,154 worth of shares (89,863 units at $15.26), increasing direct ownership by 1% to 8,621,325 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      3/20/25 7:50:25 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Springer Timothy A bought $366,354 worth of shares (20,967 units at $17.47), increasing direct ownership by 0.25% to 8,531,462 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/15/25 4:08:27 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Jewell Christopher M exercised 9,000 units of Common Stock at a strike of $3.23, increasing direct ownership by 17% to 62,490 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/13/25 4:09:06 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Technology Officer Kurtoglu Metin sold $81,790 worth of Common Stock (4,875 units at $16.78), decreasing direct ownership by 7% to 62,258 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/7/25 8:05:42 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Miljkovic Milos sold $31,542 worth of Common Stock (1,880 units at $16.78), decreasing direct ownership by 5% to 35,393 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/7/25 8:05:31 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Jewell Christopher M sold $42,783 worth of Common Stock (2,550 units at $16.78), decreasing direct ownership by 5% to 53,490 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/7/25 8:05:21 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operations Officer English Emily sold $30,149 worth of Common Stock (1,797 units at $16.78), decreasing direct ownership by 4% to 40,226 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/7/25 8:05:11 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Cartesian Therapeutics with a new price target

      BTIG Research initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $42.00

      12/19/24 8:25:53 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Cartesian Therapeutics

      TD Cowen initiated coverage of Cartesian Therapeutics with a rating of Buy

      8/6/24 6:25:49 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics downgraded by Oppenheimer

      Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform

      7/2/24 11:30:39 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Cartesian Therapeutics with a new price target

      Oppenheimer initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $50.00

      6/4/24 7:31:19 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Cartesian Therapeutics with a new price target

      Mizuho initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $40.00

      5/24/24 7:37:44 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright reiterated coverage on Cartesian Therapeutics with a new price target

      H.C. Wainwright reiterated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $54.00 from $2.00 previously

      4/23/24 6:52:35 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Cartesian Therapeutics with a new price target

      Leerink Partners initiated coverage of Cartesian Therapeutics with a rating of Outperform and set a new price target of $39.00

      4/23/24 6:28:12 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      11/18/24 9:44:37 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      10/15/24 4:30:56 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      10/4/24 6:08:15 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      9/27/24 4:20:32 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Cartesian Therapeutics Inc.

      SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      8/12/24 9:40:06 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cartesian Therapeutics Inc.

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      7/12/24 6:12:55 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Cartesian Therapeutics Inc.

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      7/5/24 4:15:23 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Cartesian Therapeutics Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      5/10/24 10:03:20 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Cartesian Therapeutics Inc. (Amendment)

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      4/12/24 4:24:02 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Cartesian Therapeutics Inc. (Amendment)

      SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      4/10/24 4:29:01 PM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Cartesian Therapeutics Inc. Financials

    Live finance-specific insights

    See more
    • Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial

      Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observed through Month 12 in Phase 2b trial Safety profile consistent with previously reported data and continues to support outpatient administration Company to host conference call and webcast with key opinion leader today at 7:30 a.m. ET FREDERICK, Md., Dec. 03, 2024 (GLOB

      12/3/24 6:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit

      FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu

      11/21/24 7:00:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces Positive Topline Results from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis

      Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin

      7/2/24 6:30:00 AM ET
      $RNAC
      Biotechnology: Pharmaceutical Preparations
      Health Care